https://www.selleckchem.com/pr....oducts/epacadostat-i
For maintenance therapy, comparing with placebo, olaparib, niraparib, veliparib, and bevacizumab are effective as maintenance therapy for certain patients with newly diagnosed stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma respectively without reducing quality of life. Longer follow-up with more mature results of overall survival will better define the effect of these agents.Over the last decade, several prognostic models have been proposed for primary central nervous system lymphoma (PCN
Curtir
Comentario
Compartilhar
